Cargando…
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in intracellular protein degradation. We describe the synthesis and properties of a novel series of non-covalent di-peptide inhibitors of the proteasome used on a capped tri-peptide that was first identified by high-throughp...
Autores principales: | Blackburn, Christopher, Gigstad, Kenneth M., Hales, Paul, Garcia, Khristofer, Jones, Matthew, Bruzzese, Frank J., Barrett, Cynthia, Liu, Jane X., Soucy, Teresa A., Sappal, Darshan S., Bump, Nancy, Olhava, Edward J., Fleming, Paul, Dick, Lawrence R., Tsu, Christopher, Sintchak, Michael D., Blank, Jonathan L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933030/ https://www.ncbi.nlm.nih.gov/pubmed/20632995 http://dx.doi.org/10.1042/BJ20100383 |
Ejemplares similares
-
Characterization of a new series of non-covalent proteasome inhibitors with exquisite
potency and selectivity for the 20S β5-subunit
por: Blackburn, C., et al.
Publicado: (2010) -
Identification
of Potent and Selective Non-covalent
Inhibitors of the Plasmodium falciparum Proteasome
por: Li, Hao, et al.
Publicado: (2014) -
Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
por: Csizmadia, Vilmos, et al.
Publicado: (2016) -
A lipid-binding loop of botulinum neurotoxin serotypes B, DC and G is an essential feature to confer their exquisite potency
por: Stern, Daniel, et al.
Publicado: (2018) -
Target Validation and Identification of Novel Boronate
Inhibitors of the Plasmodium falciparum Proteasome
por: Xie, Stanley C., et al.
Publicado: (2018)